Ketamine’s Regulatory Reckoning

Ketamine — the dissociative anesthetic that found a second life in psychiatry — is entering 2026 under more regulatory scrutiny than at any point since its clinical expansion began roughly a decade ago.

What Changed in January 2026

On January 2, 2026, HHS and the DEA jointly issued updated guidance for ketamine clinics and providers. The guidance does not create new regulations — ketamine remains a Schedule III controlled substance, and there are still no federal regulations specifically governing off-label ketamine infusion clinics — but it signals increased federal attention to how clinics document, inventory, and bill for the drug.

DEA’s Audit-Driven Approach

The DEA’s enforcement posture has shifted from chasing diversion at the individual patient level to auditing the record-keeping and billing practices of ketamine clinic operations. Because ketamine is almost always administered in clinical settings, inventory and billing records are the primary data trail. Federal prosecutors have already charged physicians at ketamine clinics with controlled substance distribution violations and healthcare fraud.

Telehealth’s Uncertain Future

DEA telemedicine flexibilities remain in place through the end of 2026 while permanent rules are developed. This matters enormously for providers who use remote prescribing models. When those flexibilities expire, permanent rules will determine whether remote ketamine prescribing survives.

Where France Is Leading

In March 2026, France’s drug regulatory agency became the first national authority anywhere in the world to authorize IV racemic ketamine specifically for adult severe suicidal crisis. The United States has only approved the S-enantiomer (esketamine/Spravato) for treatment-resistant depression under a REMS protocol.

Where the Field Disagrees

The central tension is between access and oversight. Advocates argue that the treatment gap for treatment-resistant depression is causing preventable suffering. Skeptics point to documented cases of misuse and diversion.

Why This Matters for People in Recovery

For people in SUD recovery who also have treatment-resistant depression, knowing whether a treatment program offers esketamine under appropriate clinical supervision is an increasingly relevant matching variable.

Find treatment programs addressing co-occurring mental health conditions at Rize.